- Home
- VYNE vs HOTH Comparison
VYNE vs HOTH Comparison
Compare VYNE & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- HOTH
- Stock Information
- Founded
- VYNE 2003
- HOTH 2017
- Country
- VYNE United States
- HOTH United States
- Employees
- VYNE N/A
- HOTH N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- VYNE Health Care
- HOTH Health Care
- Exchange
- VYNE Nasdaq
- HOTH Nasdaq
- Market Cap
- VYNE 16.0M
- HOTH 15.6M
- IPO Year
- VYNE 2018
- HOTH 2019
- Fundamental
- Price
- VYNE $1.46
- HOTH $1.28
- Analyst Decision
- VYNE Strong Buy
- HOTH Strong Buy
- Analyst Count
- VYNE 2
- HOTH 3
- Target Price
- VYNE $6.25
- HOTH $4.00
- AVG Volume (30 Days)
- VYNE 895.6K
- HOTH 433.6K
- Earning Date
- VYNE 08-13-2025
- HOTH 05-12-2025
- Dividend Yield
- VYNE N/A
- HOTH N/A
- EPS Growth
- VYNE N/A
- HOTH N/A
- EPS
- VYNE N/A
- HOTH N/A
- Revenue
- VYNE $605,000.00
- HOTH N/A
- Revenue This Year
- VYNE $42.51
- HOTH N/A
- Revenue Next Year
- VYNE N/A
- HOTH N/A
- P/E Ratio
- VYNE N/A
- HOTH N/A
- Revenue Growth
- VYNE 43.03
- HOTH N/A
- 52 Week Low
- VYNE $0.85
- HOTH $0.58
- 52 Week High
- VYNE $4.30
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- VYNE 56.57
- HOTH 50.15
- Support Level
- VYNE $1.10
- HOTH $1.23
- Resistance Level
- VYNE $1.49
- HOTH $1.40
- Average True Range (ATR)
- VYNE 0.15
- HOTH 0.11
- MACD
- VYNE -0.00
- HOTH -0.02
- Stochastic Oscillator
- VYNE 90.45
- HOTH 27.50
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).